- Home
- SLXN vs LIXT Comparison
SLXN vs LIXT Comparison
Compare SLXN & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- LIXT
- Stock Information
- Founded
- SLXN 2008
- LIXT 2005
- Country
- SLXN Israel
- LIXT United States
- Employees
- SLXN N/A
- LIXT N/A
- Industry
- SLXN
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- SLXN
- LIXT Health Care
- Exchange
- SLXN NYSE
- LIXT Nasdaq
- Market Cap
- SLXN 4.3M
- LIXT 4.1M
- IPO Year
- SLXN N/A
- LIXT N/A
- Fundamental
- Price
- SLXN $0.85
- LIXT $1.18
- Analyst Decision
- SLXN Strong Buy
- LIXT
- Analyst Count
- SLXN 1
- LIXT 0
- Target Price
- SLXN $5.00
- LIXT N/A
- AVG Volume (30 Days)
- SLXN 955.8K
- LIXT 31.5K
- Earning Date
- SLXN 05-21-2025
- LIXT 03-24-2025
- Dividend Yield
- SLXN N/A
- LIXT N/A
- EPS Growth
- SLXN N/A
- LIXT N/A
- EPS
- SLXN N/A
- LIXT N/A
- Revenue
- SLXN N/A
- LIXT N/A
- Revenue This Year
- SLXN N/A
- LIXT N/A
- Revenue Next Year
- SLXN N/A
- LIXT N/A
- P/E Ratio
- SLXN N/A
- LIXT N/A
- Revenue Growth
- SLXN N/A
- LIXT N/A
- 52 Week Low
- SLXN $0.21
- LIXT $1.02
- 52 Week High
- SLXN $13.56
- LIXT $3.74
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- LIXT 38.93
- Support Level
- SLXN N/A
- LIXT $1.15
- Resistance Level
- SLXN N/A
- LIXT $1.29
- Average True Range (ATR)
- SLXN 0.00
- LIXT 0.09
- MACD
- SLXN 0.00
- LIXT 0.02
- Stochastic Oscillator
- SLXN 0.00
- LIXT 10.71
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.